Processing

Please wait...

Settings

Settings

Goto Application

1. WO2003004601 - NEW ASSAYS FOR PREIMPLANTATION FACTOR AND PREIMPLANTATION FACTOR PEPTIDES

Publication Number WO/2003/004601
Publication Date 16.01.2003
International Application No. PCT/US2002/020599
International Filing Date 28.06.2002
Chapter 2 Demand Filed 28.01.2003
IPC
C07K 14/47 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
46from vertebrates
47from mammals
CPC
C07K 14/4715
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
46from vertebrates
47from mammals
4701not used
4715Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
C07K 7/06
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
7Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
04Linear peptides containing only normal peptide links
06having 5 to 11 amino acids
G01N 2333/70507
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2333Assays involving biological materials from specific organisms or of a specific nature
435from animals; from humans
705Assays involving receptors, cell surface antigens or cell surface determinants
70503Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
70507C2D
G01N 33/689
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68involving proteins, peptides or amino acids
689related to pregnancy or the gonads
Applicants
  • BIOLNCEPT, INC [US]/[US]
Inventors
  • BARNEA, Eytan
  • PEREZ, RUBEN RENEE GONZALEZ
  • LEAVIS, Paul, C.
Agents
  • KOLE, Lisa, B.
Priority Data
60/302,60702.07.2001US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) NEW ASSAYS FOR PREIMPLANTATION FACTOR AND PREIMPLANTATION FACTOR PEPTIDES
(FR) NOUVEAUX DOSAGES POUR LE FACTEUR PREIMPLANTATOIRE ET PEPTIDES DU FACTEUR PREIMPLANTATOIRE
Abstract
(EN) The present invention relates to assay methods used for detecting the presence of PIF, and to PIF peptides identified using this assay. In particular, the present invention relates to flow cytomery assays for detecting PIF. It is based, at least in part, on the observation that flow cytometry using fluorescently labeled antilymphocyte and anti-platelet antibodies demonstrated an increase in rosette formation in the presence of PIF. It is further based on the observation that flow cytometry demonstrated that monoclonal antibody binding to CD2 decreased in the presence of PIF. The present invention further relates to PIF peptides which, when added to Jurkat cell cultures, have been observed to either (I) decrease binding of anti-CD2 antibody to Jurkat cells; (ii) increase expression of CD2 in Jurkat cells; or (iii) decrease Jurkat cell viability. In additional embodiments, the present invention provides for ELISA assays which detect PIF by determining the effect of a test sample on the binding of anti-CD2 antibody to a CD2 substrate.
(FR) La présente invention concerne des méthodes de dosage utilisées pour détecter la présence de PIF; et des peptides de PIF identifiés au moyen de ce dosage. Elle concerne en particulier des dosages par cytométrie de flux destinés à détecter PIF. La méthode est fondée, au moins en partie, sur l'observation selon laquelle la cytométrie de flux utilisant des anticorps antilymphocytaires et antiplaquettaires marqués par fluorescence a révélé que l'anticorps monoclonal lié au CD2 diminuait en présence de PIF. L'invention concerne également des peptides de PIF qui, lorsqu'ils sont ajoutés à des cultures de cellules Jurkat, sont réputés soit i) diminuer la liaison de l'anticorps anti-CD2 aux cellules Jurkat; soit ii) augmenter l'expression de CD2 dans les cellules Jurkat; soit encore iii) diminuer la viabilité des cellules Jurkat. Dans une autre forme de réalisation, l'invention concerne des dosages ELISA pouvant détecter PIF par détermination de l'effet d'un échantillon d'essai sur la liaison de l'anticorps anti-CD2 à un substrat CD2.
Related patent documents
IN191/CHENP/2004This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
Latest bibliographic data on file with the International Bureau